The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas

PURPOSE: mTOR pathway hyperactivation occurs in nearly 90% of glioblastomas, but the allosteric mTOR inhibitor rapamycin has failed in the clinic. Here we examine the efficacy of the newly discovered ATP-competitive mTOR kinase inhibitors CC214-1 and CC214-2 in glioblastoma, identifying molecular de...

詳細記述

保存先:
書誌詳細
主要な著者: Gini, Beatrice, Zanca, Ciro, Guo, Deliang, Matsutani, Tomoo, Masui, Kenta, Ikegami, Shiro, Yang, Huijun, Nathanson, David, Villa, Genaro R., Shackelford, David, Zhu, Shaojun, Tanaka, Kazuhiro, Babic, Ivan, Akhavan, David, Lin, Kelly, Assuncao, Alvaro, Gu, Yuchao, Bonetti, Bruno, Mortensen, Deborah S., Xu, Shuichan, Raymon, Heather K., Cavenee, Webster K., Furnari, Frank B, James, David, Kroemer, Guido, Heath, James, Hege, Kristen, Chopra, Rajesh, Cloughesy, Timothy, Mischel, Paul S.
フォーマット: Artigo
言語:Inglês
出版事項: 2013
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3815450/
https://ncbi.nlm.nih.gov/pubmed/24030701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0527
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料